Literature DB >> 6287871

Persistence of urinary marijuana levels after supervised abstinence.

C A Dackis, A L Pottash, W Annitto, M S Gold.   

Abstract

The authors present a case report of the presence of urinary cannabinoids during 21 days of supervised abstinence from chronic marijuana use and provide data on 6 similar cases. They discuss the theoretical implications of the persistence of cannabinoids.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6287871     DOI： 10.1176/ajp.139.9.1196

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  9 in total

1.  Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.

Authors:  Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins
Journal:  J Psychopharmacol       Date:  2019-09-19       Impact factor: 4.153

2.  Psychosis from alcohol or drug abuse.

Authors:  M Lipsedge; R Littlewood
Journal:  BMJ       Date:  1988-12-17

3.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Clinical evaluation and use of urine screening for drug abuse.

Authors:  A J Saxon; D A Calsyn; V M Haver; C J Delaney
Journal:  West J Med       Date:  1988-09

5.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

6.  Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.

Authors:  Nathaniel L Baker; Kevin M Gray; Brian J Sherman; Kristen Morella; Gregory L Sahlem; Amanda M Wagner; Aimee L McRae-Clark
Journal:  Drug Alcohol Depend       Date:  2018-04-16       Impact factor: 4.492

7.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

8.  Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence.

Authors:  Robert S Goodwin; William D Darwin; C Nora Chiang; Ming Shih; Shou-Hua Li; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

9.  Exploring cannabis use and perspectives among psoriatic disease patients.

Authors:  Jackie Tsang; Orli Silverberg; Rohan Machhar; Remy Pollock; Daniel Pereira; Mitchell Sutton; Dafna D Gladman; Cheryl F Rosen
Journal:  Clin Rheumatol       Date:  2022-01-20       Impact factor: 3.650
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.